I

Iovance Biotherapeutics
D

IOVA

7.45000
USD
0.08
(1.02%)
مغلق
حجم التداول
278,688
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
2,270,616,886
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADPT
    -0.10000
    (-1.56%)
    6.31000 USD
    A
    ALLO
    0.08000
    (4.28%)
    1.95000 USD
    A
    ASTS
    0.370
    (1.62%)
    23.260 USD
    B
    BCEL
    0
    (0%)
    0.000000 USD
    C
    CRSP
    -0.220
    (-0.54%)
    40.500 USD
    F
    FATE
    -0.03500
    (-2.07%)
    1.65500 USD
    MRNA
    MRNA
    0.270
    (0.69%)
    39.630 USD
    S
    SLDB
    -0.05500
    (-1.33%)
    4.09500 USD
    المزيد
الأخبار
المقالات

العنوان: Iovance Biotherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.